knowledge -WSS

knowledge

author：focus 2025-10-01 02:15:03 - browse：8566

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Medicare drug price negotiation continues, as pharma counteroffers

WSS

Stem cell biologist probes earliest stages of human development

Multiple sclerosis has subtypes with different best treatments: study

Alzheimer's risk factor APOE4 may be a distinct form of the disease

IVF doctors demand details after CooperSurgical lawsuit

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Hollywood unions extend contract negotiations for actors

Immune cells and nerve overgrowth may explain recurring UTI pain

The cancer drug shortage isn’t new — and neither are the solutions

State of the Union pitch: Bigger Medicare drug price negotiations

Medicare proposal to cover medical devices draws a mixed reaction

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Medical leaders decry Supreme Court decision on affirmative action

A new approach to psychiatric drug development

Affirmative action in medical school literally saved lives

Republican states more likely to report Covid vaccine side effects

focus

Stem cell biologist probes earliest stages of human development

Researchers test human milk's ability to repair gut microbiome

Drug companies' payments and gifts affect physicians' prescribing

Florida health officials providing scant details on measles cases

U.K. decision on ALS drug has neurologists, advocates up in arms

Bird flu in dairy cattle: New measures to control spread to humans

hotspot

leisure time

leisure time

leisure time